These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 21052959)
1. Ten years of meta-analyses on erythropoiesis-stimulating agents in cancer patients. Tonia T; Bohlius J Cancer Treat Res; 2011; 157():217-38. PubMed ID: 21052959 [TBL] [Abstract][Full Text] [Related]
2. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Vansteenkiste J; Glaspy J; Henry D; Ludwig H; Pirker R; Tomita D; Collins H; Crawford J Lung Cancer; 2012 Jun; 76(3):478-85. PubMed ID: 22277104 [TBL] [Abstract][Full Text] [Related]
3. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients. Bohlius J; Tonia T; Schwarzer G Acta Haematol; 2011; 125(1-2):55-67. PubMed ID: 21150188 [TBL] [Abstract][Full Text] [Related]
4. Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. Bohlius J; Tonia T; Nüesch E; Jüni P; Fey MF; Egger M; Bernhard J Br J Cancer; 2014 Jul; 111(1):33-45. PubMed ID: 24743705 [TBL] [Abstract][Full Text] [Related]
5. Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis. Marchetti C; De Felice F; Palaia I; Musio D; Muzii L; Tombolini V; Benedetti Panici P Crit Rev Oncol Hematol; 2016 Mar; 99():123-8. PubMed ID: 26748593 [TBL] [Abstract][Full Text] [Related]
6. Cancer, meta-analysis and reporting biases: the case of erythropoiesis-stimulating agents. Tonia T; Schwarzer G; Bohlius J Swiss Med Wkly; 2013; 143():w13776. PubMed ID: 23740272 [TBL] [Abstract][Full Text] [Related]
7. Update on erythropoiesis-stimulating agents and clinical trials in oncology. Aapro M; Spivak JL Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512 [TBL] [Abstract][Full Text] [Related]
8. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748 [TBL] [Abstract][Full Text] [Related]
9. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Rizzo JD; Brouwers M; Hurley P; Seidenfeld J; Arcasoy MO; Spivak JL; Bennett CL; Bohlius J; Evanchuk D; Goode MJ; Jakubowski AA; Regan DH; Somerfield MR; ; J Clin Oncol; 2010 Nov; 28(33):4996-5010. PubMed ID: 20975064 [TBL] [Abstract][Full Text] [Related]
10. Pharmacovigilance in practice: erythropoiesis-stimulating agents. Hedenus M; Ludwig H; Henry DH; Gasal E Cancer Med; 2014 Oct; 3(5):1416-29. PubMed ID: 24890561 [TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis. Gao S; Ma JJ; Lu C Tumour Biol; 2014 Jan; 35(1):603-13. PubMed ID: 23959477 [TBL] [Abstract][Full Text] [Related]
13. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)? Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249 [TBL] [Abstract][Full Text] [Related]
14. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Bohlius J; Schmidlin K; Brillant C; Schwarzer G; Trelle S; Seidenfeld J; Zwahlen M; Clarke M; Weingart O; Kluge S; Piper M; Rades D; Steensma DP; Djulbegovic B; Fey MF; Ray-Coquard I; Machtay M; Moebus V; Thomas G; Untch M; Schumacher M; Egger M; Engert A Lancet; 2009 May; 373(9674):1532-42. PubMed ID: 19410717 [TBL] [Abstract][Full Text] [Related]
15. Update on safety of ESAs in cancer-induced anemia. Glaspy J J Natl Compr Canc Netw; 2012 May; 10(5):659-66. PubMed ID: 22570294 [TBL] [Abstract][Full Text] [Related]
16. Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the effect of erythropoiesis-stimulating agents in cancer patients. Rohner E; Grabik M; Tonia T; Jüni P; Pétavy F; Pignatti F; Bohlius J PLoS One; 2017; 12(12):e0189309. PubMed ID: 29228059 [TBL] [Abstract][Full Text] [Related]
17. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Bohlius J; Bohlke K; Castelli R; Djulbegovic B; Lustberg MB; Martino M; Mountzios G; Peswani N; Porter L; Tanaka TN; Trifirò G; Yang H; Lazo-Langner A Blood Adv; 2019 Apr; 3(8):1197-1210. PubMed ID: 30971397 [TBL] [Abstract][Full Text] [Related]
18. Anemia management in oncology and hematology. Spivak JL; Gascón P; Ludwig H Oncologist; 2009; 14 Suppl 1():43-56. PubMed ID: 19762516 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced anemia: the story of darbepoetin alfa. Vansteenkiste J; Wauters I; Elliott S; Glaspy J; Hedenus M Curr Med Res Opin; 2013 Apr; 29(4):325-37. PubMed ID: 23323876 [TBL] [Abstract][Full Text] [Related]
20. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Aapro M; Jelkmann W; Constantinescu SN; Leyland-Jones B Br J Cancer; 2012 Mar; 106(7):1249-58. PubMed ID: 22395661 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]